recent articles

Demystifying Alternative Asset Managers

Most retail investors who look at alternative asset managers see complexity, high fees, and wildly variable payouts, and shy away -- but some may see opportunity.

Why the Navy Needs a New Destroyer

If it doesn't get one, it may be forced to "go to war with the destroyers it has -- not the destroyers it might want or wish to have at a later time."

Is Regeneron (Finally) Getting Back on Track?

The FDA has approved Dupixent for moderate to severe eczema, and it has accepted the company's resubmission of sarilumab for rheumatoid arthritis. These drugs could give shares the shot in the arm they need.